Optimal designs for dose-escalation trials and individual allocations in cohorts

被引:0
|
作者
Duarte, Belmiro P. M. [1 ,2 ]
Atkinson, Anthony C. [3 ]
Oliveira, Nuno M. C. [2 ]
机构
[1] Inst Super Engn Coimbra, Dept Chem & Biol Engn, Inst Politecn Coimbra, Rua Pedro Nunes, P-3030199 Coimbra, Portugal
[2] Univ Coimbra, Dept Chem Engn, CIEPQPF, Rua Silvio Lima Polo 2, P-3030790 Coimbra, Portugal
[3] London Sch Econ, Dept Stat, London WC2A 2AE, England
关键词
Dose escalation experiments; Cohorts; First-in-human trials; Optimal allocation; Prognostic factors; SEQUENTIAL CLINICAL-TRIALS; BIASED COIN DESIGNS;
D O I
10.1007/s11222-022-10158-3
中图分类号
TP301 [理论、方法];
学科分类号
081202 ;
摘要
Dose escalation trials are crucial in the development of new pharmaceutical products to optimize the amount of drug administered while avoiding undesirable side effects. We adopt the framework established by Bailey (Stat Med 28(30):3721-3738, 2009. https://doi.org/10.1002/sim.3646) where the individuals are grouped into cohorts, to the subjects in which the placebo or previously defined doses are administered and responses measured. Successive cohorts allow testing higher doses of drug if negative responses have not been observed in earlier cohorts. We propose Mixed Integer Nonlinear Programming formulations for systematically computing optimal experimental designs for dose escalation. We demonstrate its application with i. different optimality criteria; ii. standard and extended designs; and iii. non-constrained (or traditional), strict halving and uniform halving designs. Additionally, we address the allocation of the individuals in a cohort considering previously known prognostic factors. To handle the problem we propose i. an enumerative algorithm; and ii. a Mixed Integer Nonlinear Programming formulation. We demonstrate the application of the enumeration scheme for allocating individuals on an individual arrival basis, and of the latter formulation for allocation on a within cohort basis.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
    Zhao, Yixuan
    Yuan, Ying
    Korn, Edward L.
    Freidlin, Boris
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 673 - 679
  • [22] Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
    Graham M. Wheeler
    Statistical Papers, 2018, 59 : 801 - 811
  • [23] Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials
    Ciraulo, DA
    Hitzemann, RJ
    Somoza, E
    Knapp, CM
    Rotrosen, J
    Sarid-Segal, O
    Ciraulo, AM
    Greenblatt, DJ
    Chiang, CN
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (02): : 179 - 192
  • [24] Phase I dose-escalation oncology trials with sequential multiple schedules
    Burak Kürsad Günhan
    Sebastian Weber
    Abdelkader Seroutou
    Tim Friede
    BMC Medical Research Methodology, 21
  • [25] Phase I dose-escalation oncology trials with sequential multiple schedules
    Guenhan, Burak Kuersad
    Weber, Sebastian
    Seroutou, Abdelkader
    Friede, Tim
    BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)
  • [26] Adaptive designs for dual-agent phase I dose-escalation studies
    Jennifer A. Harrington
    Graham M. Wheeler
    Michael J. Sweeting
    Adrian P. Mander
    Duncan I. Jodrell
    Nature Reviews Clinical Oncology, 2013, 10 : 277 - 288
  • [27] The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials
    Schwandt, A.
    Harris, P. J.
    Hunsberger, S.
    Deleporte, A.
    Smith, G. L.
    Vulih, D.
    Anderson, B. D.
    Ivy, S. P.
    CLINICAL CANCER RESEARCH, 2014, 20 (18) : 4768 - 4775
  • [28] Adaptive designs for dual-agent phase I dose-escalation studies
    Harrington, Jennifer A.
    Wheeler, Graham M.
    Sweeting, Michael J.
    Mander, Adrian P.
    Jodrell, Duncan I.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (05) : 277 - 288
  • [29] Escalation, group and A+B designs for dose-finding trials
    Ivanova, Anastasia
    STATISTICS IN MEDICINE, 2006, 25 (21) : 3668 - 3678
  • [30] The role of age on dose-limiting toxicities (DLTs) in phase I dose-escalation trials.
    Schwandt, Anita
    Harris, Pamela Jo
    Hunsberger, Sally
    Deleporte, Amelie
    Smith, Gary L.
    Vulih, Diana
    Anderson, Barry Douglas
    Ivy, S. Percy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)